Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | HTR6 | P50406 | 3/20 | 0.65 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.58 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.54 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.53 |
| ▸ | HTR3B | O95264 | 3/20 | 0.53 |
| ▸ | HTR3A | P46098 | 3/20 | 0.53 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.53 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | NCF1 | P14598 | 1/20 | 0.48 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20482315 | 0.98 | KDM4E (0.67) | ALDH1A1KDM4ELMNAHTR6ADRB1 | |
| Piperazine SCHEMBL27980528 | 0.98 | ALDH1A1 (0.67) | ALDH1A1KDM4ELMNAHTR6ADRB1 | |
| SCHEMBL4523736 | 0.93 | LMNA (0.61) | ALDH1A1KDM4ELMNAHTR6ADRB1 | |
| Bromide SCHEMBL3846722 | 0.92 | LMNA (0.59) | ALDH1A1KDM4ELMNAHTR6ADRB1 | |
| SCHEMBL3485771 | 0.84 | GPR119 (0.64) | ALDH1A1KDM4ELMNAHTR6AKR1C3 | |
| SCHEMBL31531621 | 0.83 | ALDH1A1 (0.71) | ALDH1A1KDM4ELMNAHTR6ADRB1 | |
| SCHEMBL12826096 | 0.82 | LMNA (0.59) | ALDH1A1LMNAAKR1C3GPR119TSHR | |
| SCHEMBL4518266 | 0.81 | ALDH1A1 (1.00) | ALDH1A1KDM4ELMNAHTR6ADRB1 | |
| SCHEMBL1970481 | 0.81 | LMNA (0.58) | ALDH1A1KDM4ELMNAAKR1C3GPR119 | |
| SCHEMBL709838 | 0.81 | ALDH1A1 (0.63) | ALDH1A1KDM4ELMNAHTR6ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| CN-104046246-A | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PROD & CHEM | 2014-09-17 | — | — | CN | claimed |
| US-20250388584-A1 | TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME | SHANGHAI RAISING PHARMACEUTICAL CO LTD (CN) | 2025-12-25 | — | — | US | disclosed |
| EP-4556007-A1 | TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME | Shanghai Raising Pharmaceutical Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| EP-3728234-B1 | RADIOLABELED COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2025-05-14 | — | — | EP | disclosed |
| CN-119497615-A | TPK agonists and methods of using the same for treating neurodegenerative diseases | 上海日馨医药科技股份有限公司 | 2025-02-21 | — | — | CN | disclosed |
| WO-2024012554-A1 | TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME | 上海日馨医药科技股份有限公司 | 2024-01-18 | — | — | WO | disclosed |
| WO-2023011596-A1 | AMIDE COMPOUND AND USE THEREOF | 中国药科大学 | 2023-02-09 | — | — | WO | disclosed |
| US-11541132-B2 | Radiolabeled compounds | HOFFMANN-LA ROCHE INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20210355104-A1 | ADENOSINE RECEPTOR BINDING COMPOUNDS | NIKANG THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | US | disclosed |
| WO-2005023260-A1 | 1- (2-AMINO-BENZOL) -PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005023260-A1 | 1- (2-AMINO-BENZOL) -PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | WO | disclosed |
| US-20040162282-A1 | Substituted piperazines | CHEMOCENTRYX, INC. | 2004-08-19 | — | — | US | disclosed |
| US-20040082571-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2004-04-29 | — | — | US | disclosed |
| EP-1382603-A1 | NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | Eisai Co., Ltd. (JP) | 2004-01-21 | — | — | EP | disclosed |
| WO-2003105853-A1 | 1-ARYL-4-SUBSTITUTED PIPERAZINES DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS | CHEMOCENTRYX, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| EP-0836599-A1 | 1,6-DISUBSTITUTED ISOCHROMANS FOR TREATMENT OF MIGRAINE HEADACHES | PHARMACIA & UPJOHN COMPANY (US) | 1998-04-22 | — | — | EP | disclosed |
| WO-1997002259-A1 | 1,6-DISUBSTITUTED ISOCHROMANS FOR TREATMENT OF MIGRAINE HEADACHES | PHARMACIA & UPJOHN COMPANY (US) | 1997-01-23 | — | — | WO | disclosed |
| EP-0408714-A1 | HETEROCYCLIC SULPHONYLNITROMETHANES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS. | ICI PLC (GB) | 1991-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355104-A1 | ADENOSINE RECEPTOR BINDING COMPOUNDS | ADORA2A, ADORA1, ADORA3 | ALDH1A1 944/4885KDM4E 3550/4885LMNA 3172/4885 |
| US-20040082571-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | ALDH1A1 788/4885KDM4E 3526/4885LMNA 4218/4885 |
| US-11541132-B2 | Radiolabeled compounds | SNCA, APP, BACE1 | ALDH1A1 1769/4885KDM4E 4558/4885LMNA 1833/4885 |
| US-20040162282-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | ALDH1A1 788/4885KDM4E 3526/4885LMNA 4218/4885 |
| US-20250388584-A1 | TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME | PDXK, SLC19A2, NADK | ALDH1A1 1585/4885KDM4E 4297/4885LMNA 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.